Literature DB >> 11320022

Is Posner Schlossman syndrome benign?

A Jap1, M Sivakumar, S P Chee.   

Abstract

PURPOSE: To determine the clinical course of patients with Posner Schlossman syndrome (PSS).
DESIGN: Retrospective noncomparative case series. PARTICIPANTS: Fifty-three eyes of 50 patients.
METHODS: The case notes of all patients with PSS seen at the Uveitis Clinic of Singapore National Eye Centre were reviewed for evidence of glaucoma damage and risk factors. MAIN OUTCOME MEASURES: Visual field and optic disc changes consistent with glaucoma.
RESULTS: There were 28 men and 22 women, and their mean age at onset was 35 years. Fourteen eyes (26.4%) were diagnosed to have developed glaucoma as a result of repeated attacks of PSS. Patients with 10 years or more of PSS have a 2.8 times higher risk (95% confidence interval 1.19-6.52) of developing glaucoma compared with patients with less than 10 years duration of the disease. Nine eyes (17%) underwent glaucoma filtering surgery with antimetabolites. Their postoperative follow-up ranged from 15 to 50 months (mean, 37 months). Four eyes continued to have episodes of iritis after surgery, and one of these eyes had elevated intraocular pressure during the event.
CONCLUSIONS: A significant number of patients with PSS have glaucoma develop over time, and they need to have their optic disc appearance and visual fields carefully monitored.

Entities:  

Mesh:

Year:  2001        PMID: 11320022     DOI: 10.1016/s0161-6420(01)00551-6

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  23 in total

1.  Long-term efficacy of deep sclerectomy in Posner-Schlossman syndrome.

Authors:  Fiamma Campana; Guido Caramello; Laura Dallorto; Teresa Rolle
Journal:  BMJ Case Rep       Date:  2015-01-23

2.  Posner-Schlossman syndrome induced laser in situ keratomileusis keratectasia-a case report.

Authors:  Xiu Wang; Elizabeth Wl Lim; Li Lim; Rui-Hua Wei
Journal:  Int J Ophthalmol       Date:  2017-10-18       Impact factor: 1.779

3.  Increased Complement-Associated Inflammation in Cytomegalovirus-Positive Hypertensive Anterior Uveitis Patients Based on the Aqueous Humor Proteomics Analysis.

Authors:  Jin A Choi; Hyun-Hee Ju; Jiyoung Lee; Ju-Eun Kim; Soon-Young Paik; Nikolai P Skiba; Ponugoti Vasantha Rao
Journal:  J Clin Med       Date:  2022-04-22       Impact factor: 4.964

4.  Long-term prognosis for glaucoma in patients with Posner-Schlossman syndrome.

Authors:  Jin-Ho Kim; Ji-Young Lee; Jin A Choi
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2021-07-23       Impact factor: 3.117

5.  Long-term oral therapy with valganciclovir in patients with Posner-Schlossman syndrome.

Authors:  B Sobolewska; C Deuter; D Doycheva; M Zierhut
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2013-11-28       Impact factor: 3.117

Review 6.  [Intraocular pressure related to uveitis].

Authors:  U Pleyer; P Ruokonen; C Heinz; A Heiligenhaus
Journal:  Ophthalmologe       Date:  2008-05       Impact factor: 1.059

Review 7.  [Glaucoma and uveitis. Causes of and treatment options for increased intraocular pressure in cases of inflammatory ophthalmology].

Authors:  T S Dietlein
Journal:  Ophthalmologe       Date:  2003-11       Impact factor: 1.059

8.  EDI-OCT choroidal thickness in Posner-Schlossman syndrome.

Authors:  Xiujuan Guo; Di Chen; Shuke Luo; Jinfei Huang; Yanhao Li
Journal:  Int Ophthalmol       Date:  2020-01-02       Impact factor: 2.031

9.  Human Leukocyte Antigens-B and -C Loci Associated with Posner-Schlossman Syndrome in a Southern Chinese Population.

Authors:  Jun Zhao; Tianhui Zhu; Wenjie Chen; Bao Jian Fan; Liumei He; Baocheng Yang; Zhihui Deng
Journal:  PLoS One       Date:  2015-07-10       Impact factor: 3.240

10.  The Analysis of Dynamic Changes and Prognosis of Posner-Schlossman Syndrome with Cytomegalovirus Infection and Antiviral Therapy.

Authors:  Qilian Sheng; Ruyi Zhai; Xintong Fan; Xiangmei Kong
Journal:  J Ophthalmol       Date:  2021-06-02       Impact factor: 1.909

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.